Inactive Instrument

Other languages Essex Bio-Technology Limited Deutsche Boerse AG

Equities

EB51

KYG312371035

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023	05-28
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover	03-19
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024	03-18
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-18
Essex Bio-Technology's Profit Jumps 22% in H1	23-08-17
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023	23-08-16
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial	23-07-27
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration	23-07-26
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.	23-06-13
Essex Bio-Technology Limited Announces Director Changes	23-06-09
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022	23-06-09
Essex Bio-Technology Slashes Final Dividend as 2022 Profit Falls	23-03-09
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022, Payable on 29 June 2023	23-03-08
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08
Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study	23-02-10
Essex Bio-Technology Expects 35% Fall in 2022 Profit; Shares Slip 3%	23-01-10
Essex Bio-Technology Limited Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2022	23-01-10
Essex Bio-Technology Unit Secures Patent License from Mitotech	22-10-13
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022	22-08-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Essex Bio-Technology Limited Deutsche Boerse AG

Equities

EB51

KYG312371035

Other languages

Filters